Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®)
| Autor: | L. A. Antipova, S. S. Loria, S. V. Semochkin, A. G. Rumiantsev |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Онкогематология, Vol 0, Iss 1, Pp 14-20 (2022) |
| Druh dokumentu: | article |
| ISSN: | 1818-8346 2413-4023 |
| DOI: | 10.17650/1818-8346-2009-0-1-14-20 |
| Popis: | The purpose of this study was evalueted of a long-term treatment outcome in chronic myeloid leukemia (CML) patients in accelerated phase treated with GlivecR and determination of an optimum therapy schedule. 105 patients (men — 46, women — 59) at the age from 15 till 74 years (a median age — 40 years) enrolled between 02.2001 and 02.2007 were studied. Treatment started a dose of 600 mg/day. At the insufficient primary therapy response or loss complete hematological and/or complete cytogenetic remission in the course of treatment, dose have been increased to 800 mg/day. In 82 (78.1%) patients complete hematological remissions have been reached. In 44 (41.9%) patients complete cytogenetic response (CR) is received, and in 27 (61.4 %) of them with molecular response: complete — 17 (63%) and major — 10 (27%). 6-year overall survival rate (OS) was 61.9%, 6-year event-free survival rate (EFS) — 30.5%. Achievement of complete CR was a predictor of long longterm survival rate: OS — 95.5% versus 37.7 % (р |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|